SAN DIEGO, Jan. 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI), (http://www.apricusbio.com) today announced that its research and development team at its NexMed, USA, Inc. (“NexMed, USA”) subsidiary is presenting data demonstrating the use of the Company’s proprietary NexACT® technology to improve less permeable or less soluable drugs, at the Controlled Release Society (“CRS”) Product Development Forum for Poorly Soluble Drugs, being held January 27 to 29, 2011, in Miami, Florida. The presentation, entitled, “Improved Oral Absorption of BCS 2-4 Compounds Using the NexACT® Technology” is scheduled to be presented by Richard Martin, Ph.D., Vice President, Chemistry at NexMed, USA on Thursday, January 27, 2011 from 4:30 pm to 5:45 pm EST and also on Friday January 28, 2011 from 10:50 am to 2:15 pm EST.
